Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced publication of successful multi-site validation of its software, which ...
Yong-Bum Kim, principal researcher at the Korea Institute of Toxicology (KIT), who oversaw the long-term exposure study and pathological analysis, said the pathological evaluation ensured objectivity ...